
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7785385/publications.pdf Version: 2024-02-01



KEVIN C. DINNEY

#	Article	IF	CITATIONS
1	Non-Invasive Evaluation of Acute Effects of Tubulin Binding Agents: A Review of Imaging Vascular Disruption in Tumors. Molecules, 2021, 26, 2551.	3.8	11
2	Release of Anticancer Agents in the Tumor Microenvironment Using Cathepsin B and Cathepsin L Cleavable Drug‣inker Constructs. FASEB Journal, 2021, 35, .	0.5	0
3	Imaging-Guided Evaluation of the Novel Small-Molecule Benzosuberene Tubulin-Binding Agent KGP265 as a Potential Therapeutic Agent for Cancer Treatment. Cancers, 2021, 13, 4769.	3.7	6
4	Bioreductively Activatable Prodrug Conjugates of Combretastatin A-1 and Combretastatin A-4 as Anticancer Agents Targeted toward Tumor-Associated Hypoxia. Journal of Natural Products, 2020, 83, 937-954.	3.0	15
5	Synthesis and biological evaluation of structurally diverse α-conformationally restricted chalcones and related analogues. MedChemComm, 2019, 10, 1445-1456.	3.4	9
6	Structure Guided Design, Synthesis, and Biological Evaluation of Novel Benzosuberene Analogues as Inhibitors of Tubulin Polymerization. Journal of Medicinal Chemistry, 2019, 62, 5594-5615.	6.4	19
7	Efficient synthetic methodology for the construction of dihydronaphthalene and benzosuberene molecular frameworks. Tetrahedron Letters, 2019, 60, 397-401.	1.4	5
8	Synthesis of dihydronaphthalene analogues inspired by combretastatin A-4 and their biological evaluation as anticancer agents. MedChemComm, 2018, 9, 1649-1662.	3.4	15
9	Improved Methodology for the Synthesis of a Cathepsin B Cleavable Dipeptide Linker, Widely Used in Antibody-Drug Conjugate Research. Tetrahedron Letters, 2018, 59, 3594-3599.	1.4	13
10	Mechanism of action of the vascular disrupting agent OXi8006 on activated endothelial cell signaling. FASEB Journal, 2018, 32, 804.58.	0.5	0
11	Synthesis and biological evaluation of a water-soluble phosphate prodrug salt and structural analogues of KGP94, a lead inhibitor of cathepsin L. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 1304-1310.	2.2	6
12	Bioreductively activatable prodrug conjugates of phenstatin designed to target tumor hypoxia. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 636-641.	2.2	13
13	Synthesis and biological evaluation of benzocyclooctene-based and indene-based anticancer agents that function as inhibitors of tubulin polymerization. MedChemComm, 2016, 7, 2418-2427.	3.4	35
14	Design, synthesis, and biological evaluation of water-soluble amino acid prodrug conjugates derived from combretastatin, dihydronaphthalene, and benzosuberene-based parent vascular disrupting agents. Bioorganic and Medicinal Chemistry, 2016, 24, 938-956.	3.0	37
15	Abstract 4194: Assessment of novel benzosuberene-based vascular disrupting agents (VDA) on diverse tumor lines. , 2016, , .		1
16	Structural interrogation of benzosuberene-based inhibitors of tubulin polymerization. Bioorganic and Medicinal Chemistry, 2015, 23, 7497-7520.	3.0	19
17	Mechanistic considerations in the synthesis of 2-aryl-indole analogues under Bischler–Mohlau conditions. Tetrahedron Letters, 2015, 56, 3624-3629.	1.4	4
18	Synthesis and biochemical evaluation of benzoylbenzophenone thiosemicarbazone analogues as potent and selective inhibitors of cathepsin L. Bioorganic and Medicinal Chemistry, 2015, 23, 6974-6992.	3.0	23

#	Article	IF	CITATIONS
19	The vascular disrupting activity of OXi8006 in endothelial cells and its phosphate prodrug OXi8007 in breast tumor xenografts. Cancer Letters, 2015, 369, 229-241.	7.2	26
20	Vascular Disrupting Activity of OXi8006 in Endothelial Cells and Its Phosphate Prodrug OXi8007 in Breast Tumor Xenografts in Vivo. FASEB Journal, 2015, 29, 897.5.	0.5	0
21	Evaluation of tumor ischemia in response to an indole-based vascular disrupting agent using BLI and (19)F MRI. American Journal of Nuclear Medicine and Molecular Imaging, 2015, 5, 143-53.	1.0	12
22	Abstract 1816: Assessment of anti-tumor activity of the cathepsin L inhibitor, KGP94. , 2014, , .		0
23	Synthesis and biological evaluation of indole-based, anti-cancer agents inspired by the vascular disrupting agent 2-(3′-hydroxy-4′-methoxyphenyl)-3-(3″,4″,5″-trimethoxybenzoyl)-6-methoxyindole (Bioorganic and Medicinal Chemistry, 2013, 21, 6831-6843.	OX18006).	58
24	Synthesis of a 2-Aryl-3-aroyl Indole Salt (OXi8007) Resembling Combretastatin A-4 with Application as a Vascular Disrupting Agent. Journal of Natural Products, 2013, 76, 1668-1678.	3.0	50
25	Synthesis of structurally diverse benzosuberene analogues and their biological evaluation as anti-cancer agents. Bioorganic and Medicinal Chemistry, 2013, 21, 8019-8032.	3.0	29
26	Small-molecule inhibitors of cathepsin L incorporating functionalized ring-fused molecular frameworks. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 2801-2807.	2.2	19
27	Abstract 5071: KGP94, a small-molecule cathepsin L inhibitor with antitumor activity , 2013, , .		0
28	Synthesis and Biochemical Evaluation of Thiochromanone Thiosemicarbazone Analogues as Inhibitors of Cathepsin L. ACS Medicinal Chemistry Letters, 2012, 3, 450-453.	2.8	25
29	Initial evaluation of the antitumour activity of KGP94, a functionalized benzophenone thiosemicarbazone inhibitor of cathepsin L. European Journal of Medicinal Chemistry, 2012, 58, 568-572.	5.5	29
30	An amino-benzosuberene analogue that inhibits tubulin assembly and demonstrates remarkable cytotoxicity. MedChemComm, 2012, 3, 720.	3.4	23
31	Kinetic Analysis and Antitumor Activity of Thiosemicarbazone Benzophenone Inhibitors of cathepsin L. FASEB Journal, 2012, 26, 962.7.	0.5	0
32	The effect of benzosuberene analogues on endothelial cell morphology and tube formation. FASEB Journal, 2012, 26, 999.8.	0.5	0
33	Study of a Potent Smallâ€Molecule Benzosuberene Antiâ€Cancer Agent. FASEB Journal, 2012, 26, 613.5.	0.5	0
34	A perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessment. Integrative Biology (United Kingdom), 2011, 3, 375.	1.3	87
35	Regioselective Synthesis of Water-Soluble Monophosphate Derivatives of Combretastatin A-1. Journal of Natural Products, 2011, 74, 1568-1574.	3.0	11

The Discovery and Development of the Combretastatins. , 2011, , 27-64.

3

#	Article	IF	CITATIONS
37	Abstract 1416: Development and initial evaluation of the antitumor activity of a functionalized benzophenone thiosemicarbazone inhibitor of cathepsin L. Cancer Research, 2011, 71, 1416-1416.	0.9	1
38	Design, synthesis, and biological evaluation of potent thiosemicarbazone based cathepsin L inhibitors. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 1415-1419.	2.2	39
39	Functionalized benzophenone, thiophene, pyridine, and fluorene thiosemicarbazone derivatives as inhibitors of cathepsin L. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 6610-6615.	2.2	36
40	Regio- and Stereospecific Synthesis of Mono-β-d-Glucuronic Acid Derivatives of Combretastatin A-1. Journal of Natural Products, 2010, 73, 1093-1101.	3.0	9
41	Analysis of novel low nanomolar thiosemicarbazone inhibitors of cruzain. FASEB Journal, 2010, 24, 681.5.	0.5	0
42	Carbonâ€14 radiosynthesis of combretastatin Aâ€1 (CA1) and its corresponding phosphate prodrug (CA1P). Journal of Labelled Compounds and Radiopharmaceuticals, 2009, 52, 567-570.	1.0	2
43	Application of the McMurry coupling reaction in the synthesis of tri- and tetra-arylethylene analogues as potential cancer chemotherapeutic agents. Bioorganic and Medicinal Chemistry, 2009, 17, 6993-7001.	3.0	20
44	Development of Synthetic Methodology Suitable for the Radiosynthesis of Combretastatin A-1 (CA1) and Its Corresponding Prodrug CA1P. Journal of Natural Products, 2009, 72, 414-421.	3.0	26
45	Design, synthesis and biological evaluation of dihydronaphthalene and benzosuberene analogs of the combretastatins as inhibitors of tubulin polymerization in cancer chemotherapy. Bioorganic and Medicinal Chemistry, 2008, 16, 8161-8171.	3.0	71
46	Design, synthesis, biochemical, and biological evaluation of nitrogen-containing trifluoro structural modifications of combretastatin A-4. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 5146-5149.	2.2	20
47	Combretastatin Dinitrogen-Substituted Stilbene Analogues as Tubulin-Binding and Vascular-Disrupting Agents. Journal of Natural Products, 2008, 71, 313-320.	3.0	38
48	Kinetic Studies of Potent Thiosemicarbazone Inhibitors of Cruzain. FASEB Journal, 2007, 21, A641.	0.5	0
49	Kinetics of Thiosemicarbazoneâ€Based Inhibitors of Cathepsin L. FASEB Journal, 2007, 21, A642.	0.5	0
50	Molecular Recognition of the Colchicine Binding Site as a Design Paradigm for the Discovery and Development of Vascular Disrupting Agents. , 2006, , 95-121.		6
51	Design, synthesis, and biochemical evaluation of novel cruzain inhibitors with potential application in the treatment of Chagas' disease. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 4405-4409.	2.2	68
52	Design, synthesis, and biological evaluation of combretastatin nitrogen-containing derivatives as inhibitors of tubulin assembly and vascular disrupting agents. Bioorganic and Medicinal Chemistry, 2006, 14, 3231-3244.	3.0	73
53	Synthesis and characterization of 2,6-bis-hydrazinopyridine, and its conversion to 2,6-bis-pyrazolylpyridines. Tetrahedron, 2006, 62, 3663-3666.	1.9	21
54	Synthesis and crystal structures of two novel 3,4,5- trimethoxyphenyl derivatives from (Z)-1-[(2′,3′-dinitro-4′-methoxy)-phenyl]-2-[(3″,4″,5″-trimethoxy)-phenyl] ethene. Journal of Crystallography, 2006, 36, 309-314.	Chiennical	1

#	Article	IF	CITATIONS
55	Inhibitors of cruzipain and cathepsin L. FASEB Journal, 2006, 20, A51.	0.5	Ο
56	The Discovery and Development of the Combretastatins. , 2005, , .		1
57	Combretastatin family member OXI4503 induces tumor vascular collapse through the induction of endothelial apoptosis. International Journal of Cancer, 2004, 111, 604-610.	5.1	80
58	Synthesis and biological evaluation of 2-(4-fluorophenoxy)-2-phenyl-ethyl piperazines as serotonin-selective reuptake inhibitors with a potentially improved adverse reaction profile. Bioorganic and Medicinal Chemistry, 2004, 12, 1483-1491.	3.0	10
59	Synthesis of Methoxy and Hydroxy Containing Tetralones: Versatile Intermediates for the Preparation of Biologically Relevant Molecules ChemInform, 2003, 34, no.	0.0	ο
60	Synthesis of methoxy and hydroxy containing tetralones: versatile intermediates for the preparation of biologically relevant molecules. Tetrahedron Letters, 2003, 44, 4145-4148.	1.4	21
61	Synthesis of 4-methoxy-3,5-dinitrobenzaldehyde: a correction to supposed tele nucleophilic aromatic substitution. Tetrahedron Letters, 2003, 44, 3759-3761.	1.4	3
62	Synthesis, in vitro, and in vivo evaluation of phosphate ester derivatives of combretastatin A-4. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 1505-1508.	2.2	28
63	Oxi4503, a novel vascular targeting agent: effects on blood flow and antitumor activity in comparison to combretastatin A-4 phosphate. Anticancer Research, 2003, 23, 1433-40.	1.1	52
64	2-(3-tert-Butyldimethylsiloxy-4-methoxyphenyl)-6-methoxy-3-(3,4,5-trimethoxybenzoyl)indole. Acta Crystallographica Section C: Crystal Structure Communications, 2002, 58, o330-o332.	0.4	16
65	Synthesis and biological evaluation of aryl azide derivatives of combretastatin a-4 as molecular probes for tubulin. Bioorganic and Medicinal Chemistry, 2000, 8, 2417-2425.	3.0	77
66	Preparation of New Anti-Tubulin Ligands through a Dual-Mode, Additionâ^'Elimination Reaction to a Bromo-Substituted α,β-Unsaturated Sulfoxide. Journal of Organic Chemistry, 2000, 65, 8811-8815.	3.2	44
67	A new anti-tubulin agent containing the benzo[b]thiophene ring system. Bioorganic and Medicinal Chemistry Letters, 1999, 9, 1081-1086.	2.2	115
68	Characterization and structural analyses of trimethoxy and triethoxybenzo[b]thiophene. Journal of Chemical Crystallography, 1998, 28, 289-295.	1.1	9
69	X-ray structures of two methoxybenzo[b]thiophenes. Journal of Chemical Crystallography, 1996, 26, 801-806.	1.1	3
70	Stereoselective synthesis of 2,5-dihydrofurans by sequential SN2' cleavage of alkynyloxiranes and silver(l)-catalyzed cyclization of the allenylcarbinol products. Journal of Organic Chemistry, 1993, 58, 7180-7184.	3.2	187
71	Molecular structures, conformational analysis, and preferential modes of binding of 3-aroyl-2-arylbenzo[b]thiophene estrogen receptor ligands: LY117018 and aryl azide photoaffinity labeling analogs. Journal of Medicinal Chemistry, 1993, 36, 3910-3922.	6.4	32
72	Nonsteroidal estrogens bearing acyl azide functions: potential electrophilic and photoaffinity labeling agents for the estrogen receptor. Steroids, 1992, 57, 222-232.	1.8	7

#	Article	IF	CITATIONS
73	Synthesis of a tetrafluoro-substituted aryl azide and its protio analog as photoaffinity labeling reagents for the estrogen receptor. Journal of Organic Chemistry, 1991, 56, 3125-3133.	3.2	63
74	Efficient and selective photoaffinity labeling of the estrogen receptor using two nonsteroidal ligands that embody aryl azide or tetrafluoroaryl azide photoreactive functions. Biochemistry, 1991, 30, 2421-2431.	2.5	41
75	Torsionally and hydrophobically modified 2,3-diarylindenes as estrogen-receptor ligands. Journal of Medicinal Chemistry, 1990, 33, 2726-2734.	6.4	23
76	Target tissue uptake selectivity of three fluorine-substituted progestins: Potential imaging agents for receptor-positive breast tumors. International Journal of Radiation Applications and Instrumentation Part B, Nuclear Medicine and Biology, 1990, 17, 309-319.	0.3	13
77	[3H]DU41165: A high affinity ligand and novel photoaffinity labeling reagent for the progesterone receptor. The Journal of Steroid Biochemistry, 1990, 35, 179-189.	1.1	17